What are examples of dihydropyridine calcium‑channel blockers?

Dihydropyridine Calcium Channel Blockers (DHP-CCBs)

Dihydropyridine calcium channel blockers include nifedipine, amlodipine, felodipine, isradipine, nicardipine, nisoldipine, nitrendipine, lercanidipine, lacidipine, levamlodipine, benidipine, nimodipine, and clevidipine. 1, 2, 3

Classification and Mechanism

DHP-CCBs are structurally distinct from non-dihydropyridine calcium channel blockers (diltiazem and verapamil). They work by inhibiting L-type calcium channels with high selectivity for vascular smooth muscle rather than cardiac tissue, producing predominantly peripheral arterial vasodilation with minimal effects on cardiac contractility, AV conduction, or sinus node function 3.

Commonly Used DHP-CCBs

Long-Acting Agents (Preferred)

• Amlodipine: 5-10 mg once daily 1, 2
• Felodipine: 5-10 mg once daily 1, 2
• Nisoldipine: 20-40 mg once daily 1, 2
• Nitrendipine: 20 mg once or twice daily 1, 2

Intermediate-Acting Agents

• Isradipine: 2.5-10 mg twice daily 1, 2

Short-Acting Agents

• Nifedipine: Immediate release 30-90 mg daily; slow release 30-180 mg daily 1, 2
• Nicardipine: 20-40 mg three times daily 1, 2

Intravenous Formulations

• Clevidipine: Ultra-short-acting IV agent for acute blood pressure control 4
• Nicardipine: IV formulation for acute settings 5

Key Clinical Distinctions

Critical safety consideration: Immediate-release, short-acting nifedipine must be avoided in acute coronary syndromes unless used with concomitant beta blockade, as it increases adverse cardiovascular events through reflex tachycardia and hemodynamic instability 1, 2, 1.

Second-generation DHP-CCBs (amlodipine, felodipine) have greater vascular selectivity, longer duration of action, and smaller peak-to-trough plasma concentration variations compared to first-generation agents 6. Levamlodipine demonstrates superior blood pressure reduction and the lowest adverse event profile among DHP-CCBs 7.

Common Adverse Effects

All DHP-CCBs share similar side effect profiles: systemic hypotension, headache, dizziness, flushing, palpitations, and peripheral edema (particularly ankle edema) 1, 2, 3. These effects result from their potent vasodilatory properties. Reflex tachycardia occurs more commonly with short-acting formulations 3.

Important Clinical Caveats

• Fluid retention: DHP-CCBs can cause peripheral edema that mimics worsening heart failure but does not represent true volume overload 8
• Renal considerations: When used without RAS blockade, DHP-CCBs may increase albuminuria and risk of kidney failure due to effects on intraglomerular pressure 9
• Drug interactions: All DHP-CCBs are metabolized by cytochrome P450 3A4 3
• Heart failure: While amlodipine and felodipine are reasonably tolerated in mild LV dysfunction, DHP-CCBs do not improve survival in heart failure and should be used cautiously 2, 3, 6